



LUPIN LIMITED

Registered Office: Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Corporate Identity Number: L24100MH1983PLC029442

Tel: (91-22) 6640 2323

E-mail: info@lupin.com

Website: www.lupin.com

LUPIN

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in million)				
Particulars	3 Months	3 Months	3 Months	Accounting
	Ended 30/06/2022 (Unaudited)	Ended 31/03/2022 (Audited)	Ended 30/06/2021 (Unaudited)	Year Ended 31/03/2022 (Audited)
	(Refer note 5)			
1) Revenue from operations				
a) Sales / income from operations	26,841.9	25,036.7	32,928.5	112,584.8
b) Other operating income	483.0	3,517.2	212.7	5,131.9
Total Revenue from operations	27,324.9	28,553.9	33,141.2	117,716.7
2) Other income	64.8	161.5	246.3	1,504.2
3) Total income (1+2)	27,389.7	28,715.4	33,387.5	119,220.9
4) Expenses				
a) Cost of materials consumed	6,961.2	6,755.2	6,265.4	28,169.0
b) Purchases of stock-in-trade	4,345.4	4,136.4	4,962.3	18,927.4
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade [(increase)/decrease]	428.2	(220.6)	12.2	(2,423.8)
d) Employee benefits expense	5,049.5	4,502.2	5,036.1	19,181.6
e) Finance cost	198.7	245.8	148.2	734.7
f) Depreciation, amortisation and impairment expense	1,303.5	1,310.2	1,253.6	5,141.9
g) Other expenses	8,441.9	8,779.5	7,486.5	32,987.3
h) Net (gain) / loss on foreign currency transactions	(788.3)	(397.1)	(270.5)	(665.7)
i) Business compensation expense (Refer note 3)	-	(11.7)	-	18,783.8
Total expenses	25,940.1	25,099.9	24,893.8	120,836.2
5) Profit / (Loss) before tax (3-4)	1,449.6	3,615.5	8,493.7	(1,615.3)
6) Tax expense				
Current tax (net)	289.4	555.0	2,065.6	578.0
Deferred tax (net)	(11.6)	3,419.4	(30.6)	(306.3)
Total tax expense	277.8	3,974.4	2,035.0	271.7
7) Net Profit / (Loss) after tax	1,171.8	(358.9)	6,458.7	(1,887.0)
8) Other comprehensive income / (loss)				
(a) (i) Items that will not be reclassified subsequently to profit or loss	199.8	194.3	(13.2)	37.2
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	(69.8)	(67.9)	4.6	(13.0)
(b) (i) Items that will be reclassified subsequently to profit or loss	(251.8)	(114.3)	(47.5)	(26.3)
(ii) Income tax relating to items that will be reclassified to profit or loss	60.6	23.7	11.6	12.4
Total other comprehensive income / (loss)	(61.2)	35.8	(44.5)	10.3
9) Total comprehensive income / (loss), net of tax (7+8)	1,110.6	(323.1)	6,414.2	(1,876.7)
10) Paid up equity share capital (Face value ₹ 2/- each)	909.3	909.0	907.8	909.0
11) Other equity				180,592.9
12) Earnings per share (of ₹ 2/- each) (Not annualised for the quarters)				
a) Basic (in ₹)	2.58	(0.79)	14.23	(4.16)
b) Diluted (in ₹)	2.57	(0.79)	14.18	(4.16)



See accompanying notes to the standalone financial results.

1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 03, 2022. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
2. During the quarter, 148,397 equity shares of ₹ 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by ₹ 0.3 million and securities premium account by ₹ 74.9 million.
3. During the previous year ended March 31, 2022, the Company paid an amount of USD 252.9 million (₹ 18,783.8 million) [including USD 4.9 million (₹ 374.8 million) towards litigation and settlement related expenses] towards settlement of the dispute with respect to antitrust class action filed in the U.S.A., in connection with the drug Glumetza® without admitting any liability for any wrongdoing.
4. The Company operates in one reportable business segment i.e. "Pharmaceuticals".
5. The figures for the quarter ended March 31, 2022 are the balancing figures between audited figures in respect of the full previous financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2021. The year-to-date figures up to the third quarter ended December 31, 2021 were only subject to Limited Review and not audited.

By Order of the Board
For **Lupin Limited**



Nilesh D. Gupta
Managing Director
DIN: 01734642

Place : Mumbai
Date : August 03, 2022

